Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Young Adults with Acute Lymphoblastic Leukemia Do Well on Intensified Pediatric Chemotherapy Regimen
(Posted: 11/30/2009) - Adolescents and young adults with acute lymphoblastic leukemia lived longer when treated with an intensified multi-drug chemotherapy regimen that is used to treat younger children, according to the November 1, 2009, Journal of Clinical Oncology.
- Denosumab Keeps Bones Strong during Prostate Cancer Treatment
(Posted: 10/28/2009) - Treatment with the monoclonal antibody denosumab increased bone mineral density (BMD) and reduced the risk of fractures in men who received a common treatment for prostate cancer that had not spread to other parts of the body, according to the results of a large, placebo-controlled clinical trial published in the August 20, 2009, New England Journal of Medicine.
- Weight Lifting Does Not Exacerbate and May Improve Lymphedema Symptoms After Breast Cancer
(Posted: 09/16/2009) - Slowly progressive weight lifting did not aggravate limb swelling among breast cancer survivors with lymphedema, according to a randomized clinical trial in the August 13, 2009, issue of The New England Journal of Medicine.
- Radiofrequency Ablation Effective Against Barrett Esophagus
(Posted: 07/23/2009) - In a randomized phase II trial, radiofrequency ablation led to high rates of eradication of the cell abnormalities associated with Barrett esophagus, according to the May 28, 2009, New England Journal of Medicine.
- For Children with Leukemia, Radiation May Be Unnecessary
(Posted: 07/23/2009) - Children with the most common form of leukemia can safely forego radiation therapy to prevent relapse if they are treated with chemotherapy regimens tailored to their individual needs, according to the June 25, 2009, New England Journal of Medicine.